Will larotinib/larlotinib be included in medical insurance in 2025?

Larotrectinib As a targeted therapy drug targetingNTRK gene fusion, Larotrectinib has attracted widespread attention in the field of cancer treatment in recent years. It is primarily used to treat tumors with NTRK gene fusions, including certain types of soft tissue sarcomas and non-small cell lung cancer. Since larotrectinib was approved for domestic marketing, patients have gained new treatment options, but its high price remains a barrier for many patients. However, larotrectinib has been included in my country's medical insurance, which undoubtedly provides patients with certain financial support.

OutlookWhether larotrectinib will continue to be covered by medical insurance in 2025 depends on multiple factors. First of all, the clinical effect and safety of drugs are important basis for medical insurance review. According to existing clinical studies, larotrectinib has shown good efficacy in the treatment of NTRK gene fusion-related tumors, and its overall response rate and tolerability are relatively ideal. This means that the clinical application value of larotrectinib has been recognized, and it is more likely to continue to be included in medical insurance.

Secondly, adjustments to medical insurance policies often take into account the cost-benefit ratio of drugs. Although the price of larotrectinib is relatively high, with a capsule formulation of 100mg*56 capsules costing about 20,000 yuan, compared with other anti-cancer drugs, if it has significant efficacy in a specific patient group and can improve the survival rate and quality of life of patients, the medical insurance department may re-evaluate its reimbursement standards. In addition, with the accumulation of more clinical data and follow-up results, larotrectinib's long-term efficacy and economics will also support its position in medical insurance.

Another point to note is that the inclusion of medical insurance is closely related to the country's budget, medical resource allocation and public health policy. The National Medical Insurance Administration evaluates and adjusts the existing medical insurance catalog every year. Especially in the context of the continuous emergence of new drugs, how to balance the introduction of new drugs with the sustainability of medical insurance finance is an important consideration.

Reference materials:https://www.vitrakvi.com/